# ENGAGE

Source: https://onco.cc/trials/da-trial-engage/  
OnCo record `da-trial-engage` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.

## Summary

One of two large aducanumab trials. ENGAGE did not meet its primary endpoint. The later US accelerated approval was withdrawn. Failure trials belong in a map so positive trials are not the only story.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT02477800
- Phase: 3
- Setting: Early Alzheimer’s disease
- Sponsor: Biogen
- Enrolled: 1647
- Result: Primary endpoint not met as designed. Historical context for aducanumab, which is not a current US option.
- Outcomes: Primary clinical endpoint: Aducanumab vs Placebo

## Sources

- ClinicalTrials.gov NCT02477800: https://clinicaltrials.gov/study/NCT02477800

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- drugs: [Aducanumab](https://onco.cc/drugs/da-aducanumab/)
- companies: [Biogen](https://onco.cc/companies/da-biogen/)
- roadmaps: [Anti-amyloid medicines](https://onco.cc/roadmaps/da-roadmap-anti-amyloid/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-engage.json